echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Lancet Oncol: Tisagenlecleucel for the long-term clinical prognosis of refractory/relapsed aggressive B-cell lymphoma

    Lancet Oncol: Tisagenlecleucel for the long-term clinical prognosis of refractory/relapsed aggressive B-cell lymphoma

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) therapy approved for marketing
    .


    In the JULIET flight trial, Tisagenlecleucel achieved an optimal response rate of 52% in 93 evaluable patients with relapsed/refractory aggressive B-cell lymphoma, and a complete response rate of 40%


    Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) therapy Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) )therapy

    This article reports the long-term follow-up results of the clinical prognosis, activity, and safety of the entire adult cohort
    .

    This is a multi-center, open-label, single-arm Phase 2 trial conducted at 27 treatment sites in 10 countries, recruiting histologically confirmed relapsed/refractory large B-cell lymphomas over 18 years of age The patient was given a single intravenous infusion of Tisagenlecleucel (5 x 108 CAR T cells)
    .


    The primary endpoint is the overall response rate


    Total remission

    Total remission

    From July 29, 2015 to November 2, 2017, a total of 167 patients were recruited
    .


    As of February 20, 2020, 115 patients had received Tisagenlecleucel infusion and were included in the full analysis set


    The overall response rate was 53.


    Some adverse events

    Some adverse events

    The most common grade 3-4 adverse events were anemia (39%), decreased neutrophil count (34%), decreased white blood cell count (32%), decreased platelet count (28%), and cytokine release syndrome (23%).
    %), neutropenia (20%), febrile neutropenia (17%), hypophosphatemia (13%) and thrombocytopenia (12%)
    .


    The most common treatment-related serious adverse events were cytokine release syndrome (27%), febrile neutropenia (6%), fever (5%), pancytopenia (3%), and pneumonia ( 3%)


    In summary, Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma
    .


    For patients with large B-cell lymphoma who are refractory to chemotherapy or immunotherapy or who relapse after second-line treatment, Tisagenlecleucel has advantages over traditional treatment methods in terms of risk and benefit


    Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma .


    Original source:

    Stephen J Schuster, et al.


    Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.